1. Hydroxyurea has been shown to be effective in treating atherosclerosis in ApoE-/- mice by modulating Niemann-Pick C1-like 1 protein through the gut microbiota.
2. The efficacy of hydroxyurea was verified through aortic root hematoxylin-eosin (H&E) staining and oil red O staining, as well as biochemical methods and ELISA.
3. Metabolomics methods were used to identify fecal metabolites and their changes, while immunohistochemical staining and ELISA were used for the localization and quantification of intestinal NPC1L1.
The article is generally reliable and trustworthy, as it provides evidence for its claims through a variety of methods such as aortic root hematoxylin-eosin (H&E) staining, oil red O staining, biochemical methods, ELISA, 16S rRNA sequencing, metabolomics analysis, immunohistochemical staining and ELISA. The authors also provide detailed information on the methodology used in each experiment which adds to the trustworthiness of the article. Furthermore, the authors have provided an extensive list of references which further supports their claims.
However, there are some potential biases that should be noted. Firstly, the study only focuses on ApoE-/- mice which may limit its generalizability to other populations or species. Secondly, the study does not explore any potential risks associated with hydroxyurea treatment such as side effects or long term consequences which could be important considerations when assessing its efficacy in clinical practice. Finally, although the authors provide evidence for their claims they do not present any counterarguments or alternative explanations for their findings which could add further depth to their conclusions.